Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals (NASDAQ: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Q1 2025 financial results announcement for May 14, 2025, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the quarterly results and provide a business update. Interested participants can access the call through a direct registration link, while the webcast and its replay will be available on the company's website under the Investor Relations section.

scPharmaceuticals Inc. (SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has announced its participation in three upcoming investor conferences in May 2025. CEO John Tucker will present at:

- The Citizens Life Sciences Conference on May 7 at 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20 at 10:00 a.m. ET
- Craig-Hallum 22nd Annual Institutional Investor Conference on May 28 (investor meetings only)

Webcasts of the presentations will be available on the company's website under the Investor Relations section.

scPharmaceuticals (SCPH) reported strong Q4 and full-year 2024 results, with Q4 FUROSCIX revenue reaching $12.2 million (up 99% YoY) and full-year revenue of $36.3 million (up 167% YoY). The company filled approximately 13,300 FUROSCIX doses in Q4 2024, a 23% increase from Q3.

Key highlights include FDA approval for FUROSCIX's expanded label to treat edema in chronic kidney disease patients, with launch planned for April 2025. The company reported about 3,800 unique prescribers through year-end 2024, showing 23% growth from Q3. The gross-to-net discount was 19% for Q4 and 16% for full-year 2024.

Financial position remains strong with $75.7 million in cash and cash equivalents as of December 31, 2024. However, the company reported a net loss of $18.8 million in Q4 and $85.1 million for the full year 2024.

scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Fourth Quarter and Full Year 2024 Financial Results announcement for Wednesday, March 19, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET following market close.

Management will present financial results and provide a business update during the call. Investors and interested parties can access the event through a direct registration link, with both live webcast and replay options available on the company's website under the Investor Relations section.

scPharmaceuticals (SCPH) has received FDA approval for its supplemental New Drug Application (sNDA) to expand FUROSCIX® indication to include treating edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025.

FUROSCIX is a subcutaneous injection containing 80 mg/10 mL furosemide, designed for treating edema in patients with chronic heart failure or CKD. The approval represents a significant expansion of the treatment options for patients experiencing acute fluid overload, potentially enabling them to receive treatment at home rather than requiring hospitalization.

The company has prepared for the launch through key opinion leader engagement, market research, and commercial readiness initiatives. Safety considerations include monitoring for fluid, electrolyte, and metabolic abnormalities, particularly in elderly patients and those receiving higher doses. The most common adverse reactions reported in clinical trials were site and skin reactions.

scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovation, has announced its participation in two major investor conferences in March 2025. John Tucker, President and CEO, will represent the company at both events.

The scheduled appearances include:

• A fireside chat at the 45th Annual TD Cowen Healthcare Conference on March 5 at 11:10AM ET
• A corporate presentation at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 2:20PM ET

Both presentations will be accessible via webcast through the company's website under the Investor Relations section.

scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on revolutionizing cardiorenal healthcare through patient-centric innovations, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

John Tucker, President & Chief Executive Officer, will deliver a presentation on Wednesday, February 12 at 2:40PM ET. The presentation will be accessible via webcast through the company's website under the Investor Relations section's 'News & Events' tab.

scPharmaceuticals (SCPH) reported strong preliminary Q4 2024 results, with expected net revenue between $12-12.3 million, representing 99% growth over Q4 2023. The company's full-year 2024 net revenue is anticipated to reach $36.2-36.5 million, up 167% from 2023's $13.6 million.

Q4 2024 highlights include approximately 13,300 FUROSCIX doses shipped, a 23% increase from Q3's 10,800 doses. The gross-to-net discount is expected to be 18-19%, compared to 15.7% in Q3 2024. The company ended 2024 with approximately $75.7 million in cash and cash equivalents, with accounts receivable increasing 27% from September 2024.

SCPH expanded its distribution network by adding a specialty pharmacy and anticipates growth in 2025 through Medicare redesign implementation and a potential FUROSCIX indication expansion for chronic kidney disease patients in March.

scPharmaceuticals reported strong Q3 2024 results with FUROSCIX net revenue of $10.0 million, up 164% from Q3 2023 and 24% from Q2 2024. Key achievements include FDA approval for NYHA Class IV patients, positive PK/PD data for Autoinjector program, and completion of $175 million financing. The company filled approximately 10,800 FUROSCIX doses (+16% QoQ) and expanded to 3,100 unique prescribers. However, gross-to-net discount increased to 15.7% from 8% in Q2. The company reported a net loss of $35.1 million ($0.75 per share), with $91.5 million cash on hand as of quarter-end.